DuoGenic StemCells corporation

NT$12.45As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7607—

Country Taiwan

PE (Fwd) —

TSR 3Y CAGR (24.43%)

Div yield —

ROE (77.78%)

—

Beta (5Y) —

PE TTM —

TSR TTM (19.68%)

Mkt cap NT$456.3M

ROIC (101.04%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$13

6.14%

(73.42%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

20.69

RevenueNT$M

—

—

—

—

—

—

6.862

13.67

12.05

20.69

27.10

44.47%

—

—

71.70

Revenue growth%

—

—

—

—

—

—

—

99.17

(11.82)

71.70

30.98

71.70

—

—

76.33

Gross margin%

—

—

—

—

—

—

33.63

35.85

34.04

76.33

76.47

34.94

—

—

(124.65)

Operating margin%

—

—

—

—

—

—

(488.53)

(328.42)

(506.23)

(124.65)

(100.00)

(408.47)

—

—

(127.48)

Net margin%

—

—

—

—

—

—

(496.21)

(330.99)

(510.94)

(127.48)

(100.00)

(413.60)

—

—

—

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

EV/EBITx

—

—

—

—

—

—

—

—

—

—

—

—

—

—

(4.71)

FCF yield (avg)%

—

—

—

—

—

—

—

(4.36)

(5.15)

(4.00)

(4.75)

(4.36)

—

—

(90.52)

FCF margin%

—

—

—

—

—

—

(661.60)

(326.78)

(402.72)

(90.52)

(69.60)

(364.75)

—

—

0.710

FCF / Net incomex

—

—

—

—

—

—

1.333

0.987

0.788

0.710

—

0.888

—

—

(101.04)

ROIC%

—

—

—

—

—

—

(99.93)

(123.25)

(182.47)

(101.04)

(140.04)

(112.14)

—

—

(77.78)

Return on equity%

—

—

—

—

—

—

(46.25)

(59.51)

(129.28)

(77.78)

(72.40)

(68.65)

—

—

(33.59)

Return on assets%

—

—

—

—

—

—

(41.40)

(48.12)

(103.23)

(33.59)

(52.70)

(44.76)

—

—

(0.83)

EPSNT$

—

—

—

—

—

—

(1.18)

(1.50)

(2.02)

(0.83)

(0.85)

—

—

—

58.99

EPS growth%

—

—

—

—

—

—

—

(26.50)

(34.74)

58.99

(2.74)

(26.50)

—

—

1.60

Bookvalue per shNT$

—

—

—

—

—

—

2.56

2.59

0.55

1.60

0.75

(14.51%)

—

—

(0.59)

FCF per shareNT$

—

—

—

—

—

—

(1.58)

(1.48)

(1.59)

(0.59)

(0.59)

—

—

—

—

Dividend per shNT$

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

36.65

Shares (diluted)M

—

—

—

—

—

—

28.80

30.24

30.55

31.92

◌31.92

3.49%

—

—

(4.47)

Buyback yield%

—

—

—

—

—

—

—

(5.02)

(1.03)

(4.47)

◌—

(4.47)

—

—

0.436

D/E ratiox

—

—

—

—

—

—

0.037

0.091

2.126

0.436

0.930

0.264

—

—

428.8

Enterprise valueNT$M

—

—

—

—

—

—

—

985.2

953.3

440.6

388.7

(33.13%)

—

—

—

LT debtNT$M

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Peers (US$11.03M)

Cap (US$)

PE

Health & Life Co., Ltd.

12.17M

—

EPS Bio Technology…

10.35M

—

9.967M

—

10.98M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

(28.63)

(195.0)

(195.0)

Own earn%

—

—

—

Sh yield%

(4.47)

(4.47)

(4.47)

Owners

Insiders/Inst%

53.90

2.12

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

2/3

EPS growth years

1/3

Dividend streakyrs

0

Op margin range%

−506–−125

$1 testx

—

Incr. ROIC%

—

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$20.69M

44.47%

1.00×

Cost of revenue

NT$4.898M

2.46%

0.36×

Operating expenses

NT$41.59M

5.09%

0.38×

Asset mix

Share

Trend

Cash and investments

63.32%

Other

36.68%

Reinvestment returns

No breakdown available